What is Buffalo Hump?
Buffalo hump — medically known as dorsocervical fat pad enlargement or cervicodorsal lipodystrophy — is a condition where an abnormal accumulation of fatty tissue forms at the base of the neck and upper back region. In America today, this is no longer a condition seen only in rare endocrine patients or HIV-positive individuals on antiretroviral therapy. As obesity rates continue to climb and chronic disease burdens grow, more Americans across every demographic are presenting with this once-niche diagnosis. The hump itself can range from a soft, barely-noticeable fatty lump to a large, firm mass that restricts neck movement, alters posture, and causes significant psychological distress. Doctors across the US increasingly warn that when buffalo hump appears suddenly, grows rapidly, or arrives alongside other symptoms like fatigue, muscle weakness, or skin changes, it often signals something deeper — a hormonal imbalance, an underlying metabolic disorder, or a long-term medication side effect that needs immediate clinical evaluation.
What makes buffalo hump in America in 2026 such a pressing public health conversation is the sheer size of the at-risk population. With more than 100 million American adults living with obesity, approximately 1.2 million people living with HIV, and growing numbers of patients on long-term corticosteroid therapy, the potential pool of individuals susceptible to developing dorsocervical fat accumulation has never been larger. Endocrinologists, primary care physicians, and plastic surgeons are all seeing a rise in patients presenting with this condition, and the causes are diverse — Cushing’s syndrome, prolonged glucocorticoid use, HIV-associated lipodystrophy, severe obesity, and even chronic stress-induced cortisol elevation. Understanding the statistics, risk factors, and treatment pathways behind buffalo hump in the US in 2026 is essential for both patients and healthcare providers navigating this growing health concern.
Interesting Key Facts About Buffalo Hump in the US 2026
| Fact | Detail |
|---|---|
| Medical term | Dorsocervical fat pad enlargement / Cervicodorsal lipodystrophy |
| Appearance | Soft, fatty bulge at the base of the neck or upper back |
| Primary distinction | A true buffalo hump feels soft and fatty; a “dowager’s hump” is bony (osteoporotic spinal curvature) |
| Most common cause in the US | Obesity, long-term corticosteroid use, and HIV-associated lipodystrophy |
| HIV-related prevalence | 2% to 13% of HIV-infected patients develop buffalo hump; higher (6–13%) among those with full lipodystrophy syndrome |
| Cushing’s syndrome link | Buffalo hump is a hallmark sign of Cushing’s syndrome, found in over 80% of Cushing’s patients with hypertension |
| Age of peak diagnosis | Mean age of Cushing’s syndrome diagnosis: 44 years (SD 14); buffalo hump in non-HIV patients: mean age 56.92 years |
| Gender disparity | Women are affected 3–4 times more frequently than men in pituitary-dependent cases |
| Metabolic co-morbidities | 66.7% of non-HIV buffalo hump patients have hypertension; 66.7% have diabetes; 75% have hyperlipidemia |
| Surgical success rate | The TARD liposuction technique achieves favorable outcomes in 91.1% of cases |
| Recurrence after surgery | Low recurrence rate — only 1 of 18 patients relapsed post-liposuction in a major Italian cohort |
| HIV-associated lipodystrophy rate in DC cohort | 2.5% of persons with HIV had clinically documented lipodystrophy (HAL) in a 2024 Washington DC study |
| Obesity as a driver | 40.3% of US adults have obesity (CDC/NHANES 2021–2023) — a core risk factor for buffalo hump |
| Severe obesity prevalence | 9.4–9.7% of US adults have severe obesity (BMI ≥40) — the highest-risk group for fat redistribution disorders |
| No definitive medical treatment | No FDA-approved medication specifically reverses buffalo hump; treatment is surgical or addresses the underlying cause |
Source: CDC/NCHS NHANES 2021–2023; NIH/PubMed; Journal of Clinical Medicine (MDPI) 2025; Plastic and Reconstructive Surgery Journal 2026
These facts immediately reveal the breadth of this condition’s reach in America. Buffalo hump is not a single-cause phenomenon — it sits at the intersection of endocrinology, infectious disease, metabolic medicine, and plastic surgery. The 66.7% co-prevalence of hypertension and diabetes among non-HIV buffalo hump patients is startling, suggesting the hump itself may serve as a visible external marker of serious systemic metabolic burden. For everyday Americans struggling with weight or on long-term medications, this data underscores why never dismissing a developing hump as merely cosmetic is so important.
The surgical success data is also encouraging. With 91.1% favorable outcomes reported using the TARD (Tumescent Anesthesia with Release and Debulking) liposuction technique in a 2025 Aesthetic Plastic Surgery study, and virtually zero reported recurrences in well-managed cases, patients who pursue surgical intervention with experienced surgeons do have strong outcomes. Still, given that no definitive medical therapy has been approved or widely proven to reverse buffalo hump through medication alone, prevention — particularly addressing underlying obesity, metabolic syndrome, and cortisol dysregulation — remains the most sustainable path.
Buffalo Hump Prevalence Statistics in the US 2026
| Metric | Statistic | Year |
|---|---|---|
| HIV patients with buffalo hump (general) | 1–2% of all HIV patients (cervical lipomatosis) | 2024 |
| HIV patients with lipohypertrophy (broader category) | Up to 41% of all HIV patients | 2024 |
| HIV patients with buffalo hump among those with lipodystrophy features | 6–13% | 2024 |
| HIV-associated lipodystrophy in DC cohort study | 2.5% of 12,930 persons with HIV | 2024 |
| Cushing’s syndrome diagnosed prevalence (US) | ~19,950 diagnosed cases in the US | 2024 |
| Cushing’s syndrome – female cases (US) | ~15,500 (approx. 77.7% of all cases) | 2024 |
| Cushing’s syndrome – male cases (US) | ~4,450 | 2024 |
| Cushing’s syndrome incidence (US, newer estimates) | Minimum 7.2 cases per million patient-years (University of Wisconsin) | 2024 |
| Non-HIV buffalo hump patients with mean BMI | 30.15 ± 4.59 kg/m² (obese range) | 2025 |
| Persons living with HIV in the US (total) | 1,076,732 (year-end 2023) | 2023 |
| New HIV diagnoses, US (2023) | 38,793 | 2023 |
| HIV patients on ART in the US | 76–87% prescribed ART (varies by age group) | 2023 |
Source: CDC National HIV Surveillance System (NHSS), March 2026; DelveInsight Cushing’s Disease Epidemiology Report 2024; NIH/PubMed; Journal of Clinical Medicine 2025; Medscape Endocrine Society, 2024
The prevalence data paints a nuanced picture of buffalo hump’s reach across American patient populations. The condition is most systematically tracked within HIV-positive populations because of the well-documented association between antiretroviral therapy (ART) and lipodystrophy. With over 1 million Americans living with diagnosed HIV as of year-end 2023, and between 2% and 13% of that population prone to developing dorsocervical fat accumulation, estimates place the number of HIV-associated buffalo hump cases in the US at somewhere between 20,000 and 140,000 individuals — a significant population that often remains medically underserved for this specific complication. Meanwhile, the ~19,950 diagnosed Cushing’s disease cases in the US represent only the tip of the iceberg, as research from the University of Wisconsin suggests the true incidence may be several times higher than European-based estimates imply.
The gender breakdown within Cushing’s syndrome — with women accounting for approximately 77.7% of US cases — directly corresponds to who carries the greatest risk of developing a Cushing’s-related buffalo hump. The metabolic profile of non-HIV buffalo hump patients, with a mean BMI in the obese range at 30.15, confirms that obesity itself — even without a pituitary adenoma or HIV infection — creates the metabolic environment in which dorsocervical fat accumulation occurs. These numbers demand that clinicians approach any presenting buffalo hump as a potential signal of broader metabolic or hormonal disease.
Buffalo Hump Risk Factors & Obesity Statistics in the US 2026
| Risk Factor / Metric | Statistic | Year |
|---|---|---|
| US adult obesity prevalence | 40.3% (NHANES Aug 2021–Aug 2023) | 2024 |
| US adult severe obesity prevalence | 9.4–9.7% (BMI ≥40) | 2024 |
| US adult overweight + obesity combined | 72.4% of adults aged 20+ | 2024 |
| Obesity in adults aged 40–59 | 46.4% — highest among all age groups | 2024 |
| States with obesity prevalence ≥35% | 17 states (BRFSS 2024 data) | 2024 |
| Midwest obesity prevalence | 35.9% (highest by US region, 2024) | 2024 |
| South obesity prevalence | 34.5% | 2024 |
| Black adult obesity prevalence | Highest rate of any racial group; 38 states had ≥35% prevalence | 2024 |
| Annual healthcare cost of obesity | Nearly $173 billion (in 2019 dollars) | CDC estimate |
| Corticosteroid use — long-term trend | Glucocorticoid use increased over 2 decades despite treatment advances | 2024 |
| Atopic dermatitis patients on oral corticosteroids within 6 months of diagnosis | 20% (US claims data 2017–2024) | 2026 |
| HIV on ART – ages 50+ | 87% prescribed ART, 68% fully adherent — highest adherence group | 2023 |
Source: CDC/NCHS Data Brief No. 508, September 2024; CDC Adult Obesity Prevalence Maps, December 2025; CDC Medical Monitoring Project 2023 Cycle; PubMed/PMC corticosteroid studies 2024–2025
The obesity crisis in America is the single most powerful background driver of buffalo hump prevalence in the broader US population. With 40.3% of American adults living with obesity and over 72% classified as overweight or obese, the pool of people whose bodies are metabolically primed for abnormal fat distribution — including at the dorsocervical region — is immense. Middle-aged adults aged 40–59 carry the heaviest obesity burden at 46.4%, which aligns almost precisely with the peak age range for both Cushing’s diagnosis and non-HIV buffalo hump presentations (mean age 56.92 years in published clinical series). The South and Midwest, regions with consistently the highest obesity rates, likely bear a disproportionate burden of obesity-related buffalo hump cases as well.
Long-term corticosteroid use is the other major modifiable risk factor, and the data suggests it is not decreasing. Despite advances in targeted therapies for inflammatory conditions, glucocorticoid prescribing has increased over the past two decades across the US population. The fact that 20% of atopic dermatitis patients in a large US claims database were placed on oral steroids within just 6 months of diagnosis illustrates how routinely these medications enter long-term use, creating chronic exposure to the elevated cortisol-like effects that drive dorsocervical fat deposition. Taken together, rising obesity and persistent steroid use form a perfect storm for continued growth in buffalo hump cases across America through 2026 and beyond.
Buffalo Hump Symptoms in the US 2026
| Symptom Category | Specific Symptoms | Frequency / Note |
|---|---|---|
| Primary physical sign | Soft, fatty bulge at the base of the neck / upper back | Hallmark presenting sign |
| Postural changes | Restricted neck movement, abnormal posture, forward head tilt | Reported in 100% of surgical cases in Italian cohort |
| Back and neck pain | Chronic upper back pain, neck stiffness | Common in cases with large fat pads |
| Cushing’s syndrome symptoms | Weight gain (especially central), round “moon” face, easy bruising, stretch marks, muscle weakness | Present when Cushing’s is the cause |
| HIV lipodystrophy symptoms | Buffalo hump + peripheral fat loss (face, arms, legs), breast enlargement, abdominal protrusion | Combined pattern in HIV-related cases |
| Metabolic symptoms | High blood pressure (~80% of Cushing’s patients), high blood sugar, high cholesterol | Common co-morbidities |
| Neurological/functional | Transient numbness post-surgery (26.7% resolved within 6 months) | Post-surgical, resolves |
| Psychological symptoms | Poor self-esteem, body image distress, anxiety, depression | Well-documented in HIV-associated and Cushing’s cases |
| Hormonal symptoms | Irregular periods, low libido, skin thinning | When caused by cortisol excess or hormonal imbalance |
| Stress-related pathway | Elevated cortisol from chronic stress leading to fat deposits in the neck and upper back | Increasingly recognized in non-HIV, non-Cushing’s patients |
Source: Cleveland Clinic Health Library 2025; NIH NCBI StatPearls – HIV-Associated Lipodystrophy; Journal of Clinical Medicine (MDPI) 2025; Aesthetic Plastic Surgery 2025
Symptoms of buffalo hump in the US in 2026 span a wide clinical spectrum, from the merely cosmetic to the functionally debilitating. The hallmark symptom is the soft, palpable fatty bulge at the dorsocervical region — but the surrounding symptom picture tells the more important story. When a buffalo hump arrives alongside a round face, easy bruising, purple stretch marks, and unexplained weight gain concentrated in the abdomen, Cushing’s syndrome must be ruled out immediately. When it appears in a patient on HIV antiretrovirals alongside peripheral fat loss in the face and limbs, HIV-associated lipodystrophy is the likely culprit. The 100% rate of restricted neck movement documented in the Italian surgical cohort is a sobering reminder that left untreated, large buffalo humps are not cosmetic inconveniences — they create real functional disability.
Mental health consequences are also significant and often underappreciated. Body image distress, anxiety, and social withdrawal are well-documented sequelae in both Cushing’s patients and HIV-positive individuals with visible body fat redistribution. American healthcare providers need to treat the psychological burden of buffalo hump as seriously as the physical one, incorporating mental health screening and support into any comprehensive treatment plan. The fact that chronic stress itself — via elevated cortisol — can contribute to dorsocervical fat deposition even without a formal Cushing’s diagnosis adds yet another layer to the condition’s complexity in the high-stress, high-obesity American healthcare landscape of 2026.
Buffalo Hump Causes & Associated Conditions in the US 2026
| Cause / Associated Condition | US Statistic / Prevalence | Notes |
|---|---|---|
| Cushing’s syndrome (endogenous) | ~19,950 diagnosed US cases; incidence 7.2+ per million | Pituitary adenoma (60–80% of cases), adrenal tumor, ectopic ACTH |
| Long-term corticosteroid use (exogenous Cushing’s) | Glucocorticoid prescribing increased over 2 decades in the US | Most common iatrogenic cause |
| HIV-associated lipodystrophy | 1,076,732 people with diagnosed HIV in the US (year-end 2023); 2–13% develop buffalo hump | ART-related fat redistribution, especially older regimens |
| Obesity / metabolic syndrome | 40.3% of US adults obese; 72.4% overweight or obese | Strongest population-level driver |
| Hyperinsulinemia | Independently associated with buffalo hump in HIV-positive patients (P ≤0.007) | Risk factor in both HIV and non-HIV contexts |
| Hypertension (co-cause/co-morbidity) | 66.7% in non-HIV buffalo hump patients; ~80% in Cushing’s syndrome | Bidirectional relationship with cortisol |
| Type 2 diabetes (co-cause/co-morbidity) | 66.7% in non-HIV buffalo hump patients | Metabolic cluster |
| Hyperlipidemia | 75% of non-HIV buffalo hump patients | Part of systemic metabolic burden |
| Madelung’s disease (rare) | Rare benign fatty tumor condition; idiopathic bilateral lipomatosis | Non-metabolic cause |
| Genetics | Family history increases individual susceptibility | No specific gene identified |
Source: Journal of Clinical Medicine (MDPI), August 2025; CDC NHSS March 2026; DelveInsight Epidemiology Report 2024; NIH/PubMed; CDC NHANES 2021–2023
The causal landscape of buffalo hump in the United States in 2026 is remarkably diverse, spanning from rare pituitary tumors to mass-population phenomena like obesity and widespread steroid prescribing. Cushing’s syndrome remains the most clinically significant single cause — the combination of excess cortisol and pituitary or adrenal pathology drives fat preferentially to the dorsocervical region, abdomen, and face. But in absolute numbers across the US population, obesity-driven fat redistribution and long-term steroid use likely account for far more buffalo hump cases than Cushing’s alone, simply because of the scale at which these conditions affect Americans. The 40.3% obesity prevalence and decades-long trend of increasing glucocorticoid prescribing together represent a much larger reservoir of risk than the ~20,000 diagnosed Cushing’s cases in the country.
The tight clustering of hypertension (66.7%), diabetes (66.7%), and hyperlipidemia (75%) in non-HIV buffalo hump patients, documented in peer-reviewed 2025 research, is clinically revelatory. It strongly suggests that in patients who develop a buffalo hump outside of HIV or confirmed Cushing’s syndrome, clinicians should perform a comprehensive metabolic workup — because the visible hump may be the first externally detectable marker of a deep metabolic syndrome already in progress. The role of hyperinsulinemia as an independent risk factor (demonstrated in HIV-positive patients with buffalo hump, P≤0.007) further ties this condition to insulin resistance and the broader metabolic dysfunction affecting tens of millions of Americans.
Buffalo Hump Prevention in the US 2026
| Prevention Strategy | Evidence / Statistic | Target Population |
|---|---|---|
| Weight management and obesity prevention | Reducing obesity from 40.3% to the Healthy People 2030 goal of 36% | All US adults |
| Healthy diet and physical activity | Reduces visceral and regional fat deposition; addresses root cause | General population |
| Limiting long-term corticosteroid use | Long-term OCS use (>90 days) associated with elevated adverse outcomes; guidelines recommend restricting use | Patients on glucocorticoids |
| Switching to safer ART regimens | Newer ART regimens (tenofovir alafenamide/TAF-based) dramatically reduce lipodystrophy risk | HIV-positive Americans on ART |
| Early HIV treatment and monitoring | 82.8% of new 2023 HIV diagnoses linked to care within 1 month; early ART limits lipodystrophy development | Newly diagnosed HIV patients |
| Cortisol and stress management | Elevated cortisol from chronic stress drives fat deposition in the neck and upper back | High-stress populations |
| Regular metabolic screening | Lipid panel, glucose, blood pressure monitoring for those on steroids or with HIV | Patients on ART or glucocorticoids |
| Monitoring body composition in HIV patients | Abdominal girth, hip, and mid-upper arm circumferences; BMI tracking | All ART patients |
| Screening for Cushing’s syndrome | Clinical suspicion in patients with central obesity + hypertension + uncontrolled diabetes | At-risk patients, not general population |
| Avoiding medications that promote cortisol elevation | Includes certain antidepressants, antipsychotics, and corticosteroids | Patients on long-term medication regimens |
Source: NIH StatPearls – HIV-Associated Lipodystrophy; CDC Adult Obesity Facts; CDC National HIV Prevention and Care Objectives 2025; Wikipedia – HIV-Associated Lipodystrophy (March 2026); Healthy People 2030
Prevention of buffalo hump in America in 2026 is fundamentally tied to three converging public health battles: the obesity epidemic, safe medication management, and optimized HIV care. The most impactful single-population prevention measure is reducing obesity rates — the CDC’s own Healthy People 2030 target of bringing adult obesity below 36% from its current 40.3% would meaningfully reduce the metabolic environment that promotes abnormal regional fat deposition, including at the dorsocervical region. For the HIV-positive population, transitioning from older nucleoside analog and protease inhibitor regimens to modern ART — particularly tenofovir alafenamide (TAF)-based regimens — has already dramatically reduced lipodystrophy incidence, and continuing this shift in the 76–87% of HIV patients currently on ART is the cornerstone of HIV-related buffalo hump prevention.
The role of stress and cortisol management as a genuine prevention strategy is an emerging theme in 2026. With cortisol elevation from chronic psychological stress now recognized as a contributor to dorsocervical fat deposition even in otherwise healthy individuals, behavioral interventions — stress reduction, sleep optimization, and anxiety management — are becoming part of a holistic prevention conversation. For patients on long-term corticosteroids, clinical guidelines increasingly emphasize the minimum effective dose and duration, with restriction of oral corticosteroid use beyond 90 days associated with meaningfully higher risk of adverse body composition changes. Proactive monitoring of waist circumference, BMI, lipid profiles, and blood pressure in all patients on ART or long-term steroid therapy gives clinicians the earliest possible warning that fat redistribution is beginning — potentially before a visible hump has formed.
Buffalo Hump Treatment Options in the US 2026
| Treatment Option | Details / Outcome Data | Best For |
|---|---|---|
| Treating underlying cause | Addressing Cushing’s syndrome, adjusting ART, stopping steroids | First-line approach for all patients |
| Transsphenoidal surgery (pituitary) | First-line for Cushing’s disease; highest remission rates at specialized centers | Pituitary-dependent Cushing’s |
| Liposuction (standard) | Most common surgical approach; minimally invasive; effective for fat removal | General buffalo hump cases |
| VASER ultrasound-assisted liposuction | Effective even for fibrous-dense fat; good clinical results, high patient satisfaction; no recurrences at 2-year follow-up in published series | Fibrosis-rich humps, HIV-related cases |
| TARD technique (minimally invasive) | Favorable outcomes in 91.1% of cases; transient numbness 26.7% (resolved within 6 months); no infection/hematoma | All buffalo hump types |
| Dissector-assisted liposuction | 57 patients, zero complications; average hump volume 328.72 mL; significant improvement on all 4 clinical parameters | Fibro-lipodystrophy humps |
| Excisional lipectomy | Direct fat removal; more scarring and longer recovery than liposuction; effective for large or very fibrous humps | Complex, fibrosis-dominant cases |
| Tesamorelin (GHRH analog) | FDA-approved to treat HIV-associated visceral fat accumulation; used for lipodystrophy management | HIV-associated lipodystrophy |
| Medical therapy (Cushing’s) | Steroidogenesis inhibitors, ACTH-lowering agents, glucocorticoid receptor antagonists; adjunct to surgery | Cushing’s syndrome cases |
| ART regimen modification | Switching from older to newer regimens reduces ongoing fat redistribution | HIV-positive patients |
| Lifestyle intervention | Diet, exercise, weight loss — may reduce fat overall but rarely fully resolves a buffalo hump | Mild/early cases; prevention |
Source: Cleveland Clinic Health Library 2025; Plastic and Reconstructive Surgery Journal, February 2026; Aesthetic Plastic Surgery 2025; NIH StatPearls; ScienceDirect – Cushing’s Syndrome 2023
Treatment of buffalo hump in the US in 2026 has advanced substantially on the surgical front, while medical management continues to depend heavily on addressing the root cause. For the majority of patients — whether their hump is driven by obesity, Cushing’s, steroid use, or HIV lipodystrophy — the most durable approach remains identifying and treating the underlying condition first. In Cushing’s syndrome cases, transsphenoidal surgery at specialized pituitary tumor centers achieves the highest remission rates and may reduce or resolve the hump over time once cortisol normalizes. For HIV patients, switching to modern TAF-based ART regimens stops further fat accumulation and may allow partial reversal, though established humps rarely fully regress without surgical intervention.
When surgery is warranted, the evidence strongly favors liposuction over excisional lipectomy in nearly all cases. The newly published TARD technique (2025 Aesthetic Plastic Surgery) and dissector-assisted liposuction (February 2026 Plastic and Reconstructive Surgery Journal) represent the current state-of-the-art, with the TARD approach achieving 91.1% favorable outcomes and the dissector-assisted technique reporting zero complications in 57 patients with an average hump volume of 328.72 mL. The minimal scarring, rapid recovery (many patients return to normal activities within days), and very low recurrence rates make modern liposuction approaches an attractive option for eligible patients. VASER ultrasound-assisted liposuction remains particularly well-suited to the fibrous, fibrosis-rich humps commonly seen in long-standing HIV-associated lipodystrophy cases. For patients where surgery is not an option, tesamorelin (a GHRH analog) offers an FDA-recognized pharmacological pathway specifically validated for HIV-associated body fat redistribution.
Buffalo Hump & HIV-Associated Lipodystrophy Statistics in the US 2026
| Metric | Statistic |
|---|---|
| Total persons with diagnosed HIV in the US | 1,076,732 (year-end 2023) |
| New HIV diagnoses in the US (2023) | 38,793 |
| HIV patients with any lipodystrophy (DC Cohort, 2011–2024) | 2.5% (325 of ~12,930) |
| HIV-associated lipodystrophy cases — male | 75% of HAL cases |
| HIV-associated lipodystrophy — non-Hispanic Black | 61% of HAL cases |
| Lipohypertrophy prevalence in HIV patients (any form) | Up to 41% |
| Buffalo hump specifically in HIV patients | 1–2% (cervical lipomatosis) |
| Buffalo hump among those with lipodystrophy syndrome | 6–13% |
| HIV-related deaths in the US (2023) | 4,496 |
| HIV viral suppression rate (2023) | 67.2% of those living with diagnosed HIV |
| HIV patients linked to care within 1 month (2023) | 82.8% |
| ART adherence – ages 50+ (2023) | 87% prescribed ART; 68% took all doses |
Source: CDC National HIV Surveillance System (NHSS), March 2026; CDC Medical Monitoring Project 2023 Cycle; PubMed (DC Cohort study, April 2026); NIH Bookshelf – HIV-Associated Lipodystrophy
HIV-associated buffalo hump represents one of the most precisely tracked and clinically studied manifestations of this condition in the United States. With 1,076,732 Americans living with diagnosed HIV at year-end 2023 and 38,793 new diagnoses in 2023 alone, the base population at risk for HIV-associated lipodystrophy — and by extension, buffalo hump — remains substantial. The recent DC Cohort study (published April 2026, covering 2011–2024) provides some of the most current real-world US data available, documenting HAL in 2.5% of persons with HIV — with striking demographic patterns: 75% male and 61% non-Hispanic Black. These disparities reflect both the demographics of HIV in America and potentially differential access to newer, lower-lipodystrophy-risk ART regimens.
The 67.2% viral suppression rate and 82.8% linkage to care within one month among newly diagnosed HIV patients in 2023 are genuinely encouraging metrics — a well-treated HIV population on modern ART experiences far less lipodystrophy than earlier generations of patients. Yet the persistence of buffalo hump even on newer regimens (as documented in case reports involving raltegravir and atazanavir) confirms that the condition hasn’t been fully eliminated by ART advances. The disproportionate burden carried by non-Hispanic Black and male patients with HIV in America means that targeted outreach, culturally competent care, and equitable access to the most modern ART formulations remain essential to reducing HIV-related buffalo hump prevalence in 2026 and beyond.
Buffalo Hump & Cushing’s Syndrome Statistics in the US 2026
| Metric | Statistic |
|---|---|
| US diagnosed Cushing’s disease prevalence (2024) | ~19,950 cases |
| Female Cushing’s disease cases (US) | ~15,500 (~77.7% of all cases) |
| Male Cushing’s disease cases (US) | ~4,450 |
| Adult Cushing’s disease cases (US) | ~17,950 |
| Pediatric Cushing’s disease cases (US) | ~2,000 |
| US incidence (Wisconsin/newer estimate) | Minimum 7.2 cases per million patient-years |
| Global prevalence estimate | 57–79 cases per million (all causes) |
| Female-to-male ratio | 4:1 globally |
| Mean age at Cushing’s diagnosis | 44 years (SD 14) |
| ACTH-dependent Cushing’s | 70–80% of all cases |
| Hypertension prevalence in Cushing’s | ~80% of Cushing’s syndrome patients |
| Buffalo hump as a hallmark sign | Present as a classic feature of Cushing’s syndrome |
Source: DelveInsight Cushing’s Disease Epidemiology Forecast 2024; Expert Market Research Epidemiology Forecast 2026–2035; ScienceDirect Cushing’s Syndrome Review 2023; Medscape Endocrine Society 2024
Cushing’s syndrome is the definitive endocrine condition behind buffalo hump, and its statistics in the US in 2026 tell a compelling story of both underdiagnosis and growing clinical awareness. The ~19,950 diagnosed cases as of 2024 represent only those formally captured in clinical databases — the University of Wisconsin data presented at the 2024 Endocrine Society annual meeting suggests that actual US incidence may be nearly 3–7 times higher than previously recognized European-based estimates. The strong female predominance (77.7% of US Cushing’s disease cases are in women, reflecting the global 4:1 ratio) means that any American woman presenting with central weight gain, a visible hump at the base of her neck, round face, and easy bruising should receive cortisol testing without delay.
The ~80% prevalence of hypertension among Cushing’s syndrome patients — combined with the buffalo hump as a physical hallmark — creates a recognizable clinical pattern that should prompt urgent investigation. Yet because many features of Cushing’s syndrome (central obesity, hypertension, glucose intolerance) overlap with common conditions in the broader obese American population, the diagnosis is frequently delayed by years. Increased education for primary care providers about the clinical triad of central obesity, buffalo hump, and purple striae could meaningfully shorten this diagnostic gap and improve outcomes for the estimated tens of thousands of Americans who may currently be living with undiagnosed Cushing’s syndrome and its associated buffalo hump.
This article was produced for informational and educational purposes only and does not constitute medical advice. All statistics are sourced from US government and peer-reviewed scientific publications. Readers should consult a qualified healthcare professional for diagnosis and treatment decisions.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
